AI Safety, Ethics & Governance

82% of global in vivo CAR-T therapies are being developed in China — a data point from Nature’s September 28, 2026 report that reveals a new paradigm for innovation governance. This isn’t just about biotech; it’s a blueprint for how AI safety might evolve: not through slow, centralized review, but through fast, decentralized, real-world testing with adaptive ethical frameworks. How can we design AI safety systems that learn as fast as China’s medical trials? What if regulatory speed, not rigidity, becomes the ultimate safety feature? The answer may lie in the same fast-track pathways that are accelerating life-saving therapies today. This insight comes directly from: https://www.nature.com/articles/d41586-026-03004-3?error=cookies_not_supported&code=2a3cebc0-8d2a-4159-9ba7-f1a3ba0133a0 Source: https://www.nature.com/articles/d41586-026-03004-3?error=cookies_not_supported&code=2a3cebc0-8d2a-4159-9ba7-f1a3ba0133a0 View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request.